The global hematology analyzers market is estimated to grow with a moderate CAGR during the forecast period, i.e., 2022-2030. The market for hematology analyzers is mainly projected to grow owing to factors such as the growing number of blood donations and rising incidences of blood disorders. In 2018, more than 210,000 people were diagnosed with hemophilia, which increased up to about 324,000 in the year 2019. Moreover, the rising use of hematology analyzers in research and development activities in various areas such as pharmacogenomics, genetic therapies, bleeding disorders, stem cell research, and proteomics is also expected to propel market growth. Furthermore, factors such as the rise in public awareness and the consolidation of diagnostic laboratory chains are expected to drive the market growth in the forecast period. Additionally, the rising adoption rate of automated hematology instruments and integration of AI-based hematology analyzers combined with growing preferences towards high sensitivity hematology testing is also anticipated to drive the market growth in the near future.
The market is segmented based on product type into 3-part hematology analyzer, 5-part hematology analyzer, point-of-care testing hematology analyzer, and others. The 3-part hematology analyzer segment is anticipated to grab the most significant share by the end of 2030, ascribing to the fact that 3-part hematology provides sufficient information for most clinical settings and is highly cost-effective. CLICK TO DOWNLOAD SAMPLE REPORT
Based on end-users, the clinical laboratories segment in the global hematology analyzers market is projected to grow with a significant CAGR over the forecast period. The segment's growth can be attributed to the fact that clinical laboratories are early adopters of advanced technological equipment, and an increasing number of hematological tests are conducted here. Moreover, as clinical laboratories provide convenience and accurate results, the market segment is expected to grow significantly in the upcoming years.
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.74 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.31 in 2008 to USD 1,110.84 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Geographically, the global hematology analyzers market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia Pacific is predicted to grow at the highest CAGR over the forecast period. This can be attributed to the presence of emerging opportunities, mainly in the developing economies of China and India. Moreover, growing awareness regarding better health care facilities, rising occurrences of diseases, and increasing population in the countries are also expected to fuel the growth of the market in the region. Furthermore, in 2030, the market in North America is evaluated to occupy the largest share in terms of revenue owing to the increasing burden of blood disorders in the region. For instance, according to the World Health Organization, anemia which is a common blood disorder, affects more than three million Americans, particularly adolescent women. Additionally, the growth in the adoption of hematology analyzers by the diagnostic industry and growing technological advancements in diagnostic instruments in the region are expected to fuel market growth in the future.
The global hematology analyzers market is further classified on the basis of region as follows:
Our in-depth analysis of the global hematology analyzers market includes the following segments:
FREQUENTLY ASKED QUESTIONS
The growth in blood donations and increasing technological advancements in hematology analyzers are the key factors driving market growth.
The market is anticipated to attain a moderate CAGR over the forecast period, i.e., 2022-2030
Stringent regulatory policies for hematology analyzers and high cost of the product are estimated to hamper market growth.
The market in Asia Pacific region will provide ample growth opportunities owing to the increasing population, rising investments in healthcare facilities and infrastructure in the region.
The major players dominating the hematology analyzers market are Abbott Laboratories, Beckman Coulter, HORIBA Ltd, Siemens AG, Nihon Kohden Corporation, among others.
The company profiles are selected on the basis of revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by product type, end-users and region.
With respect to end-users, the clinical laboratories segment is anticipated to hold the largest market share owing to the fact that clinical laboratories are early adopters of advanced technological equipment.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization